Exelixis
EXEL
#1855
Rank
โ‚น1.020 T
Marketcap
โ‚น3,790
Share price
-2.18%
Change (1 day)
32.84%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น218.11. In 2023 the company made an earnings per share (EPS) of โ‚น59.87 an increase over its 2022 EPS that were of โ‚น52.24.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น59.8714.61%
2022โ‚น52.24-22.97%
2021โ‚น67.81100%
2020โ‚น33.91-65.09%
2019โ‚น97.14-53.91%
2018โ‚น210.77333.96%
2017โ‚น48.57-260.61%
2016-โ‚น30.24-58.75%
2015-โ‚น73.31-42.45%
2014-โ‚น127.385.3%
2013-โ‚น120.97

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น956.68 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น157.62-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,194 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น339.59 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น695.90 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น272.17 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น329.53 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น336.32-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น76.98-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA